HOME >> BIOLOGY >> NEWS
NIAMS funds multicenter study of surgical vs. nonsurgical treatment of back pain

Surgical versus nonsurgical treatment of three back disorders will be studied in 1,450 patients at 11 medical centers with funds awarded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health (NIH). Researchers at these centers will compare the two treatment approaches in patients who have a herniated (bulging) lumbar disc, spinal stenosis (narrowing of the canal through which the spinal cord passes) or degenerative spondylolisthesis, where a vertebra in the spine slips forward out of place. This project is expected to have a major impact on clinical practice and on the cost of medical services for persons with one of the three back disorders.

The 5-year study, which will cost more than $13.5 million, is being performed under the direction of James N. Weinstein, D.O., M.S., professor in the Department of Community and Family Medicine, Center for the Evaluative Clinical Sciences, and professor of surgery at Dartmouth Medical School. Participating centers include: Case Western Reserve University (Cleveland, Ohio), Dartmouth Medical School (Hanover, N.H.), Emory Spine Center (Decatur, Ga.), the Hospital for Special Surgery (New York, N.Y.), Rothman Institute (Philadelphia, Pa.), Nebraska Spine Surgeons, PC (Omaha, Neb.), Rush-Presbyterian-St. Luke Medical Center (Chicago, Ill.), University of California (San Francisco, Calif.), The Hospital for Joint Diseases (New York, N.Y.), Washington University (St. Louis, Mo.) and William Beaumont Hospital (Royal Oak, Mich.).

Patients enrolled in the study will be randomly assigned to either surgical or nonsurgical treatment. In the nonsurgical group, treatments will be prescribed according to the diagnosis and duration of the condition. Among the nonsurgical treatments included in the study are: 1-3 days of bed rest, physical therapy, home exercise, epidura
'"/>

Contact: Judith Wortman
wortmanj@exchange.nih.gov
301-496-8190
NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases
23-Sep-1999


Page: 1 2

Related biology news :

1. NIAMS funds the North American Spondylitis Consortium
2. NIGMS funds Center for Quantitative Biology
3. $5 million grant funds partnership, studies of minority-based issues in reproductive health
4. NIH funds new Boston College-Boston University study of B-1a cell associated with leukemia
5. NSF funds summer research program abroad for undergraduates at UC San Diego
6. Research to create lung-cancer blood tests receives $3.4M in Pennsylvania tobacco settlement funds
7. The DFG funds a new research vessel
8. NIH funds Breast Cancer and the Environmental Research Center at Fox Chase Cancer Center
9. Grant funds research to develop tissue-engineered solutions for heart disease
10. Stuart research funds generating dividends for veterinary medicine
11. Grant funds research to develop microbicide barrier to HIV

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/16/2016)...   EyeLock LLC , a market leader of ... an IoT Center of Excellence in Austin, ... of embedded iris biometric applications. EyeLock,s iris ... security with unmatched biometric accuracy, making it the most ... EyeLock,s platform uses video technology to deliver a fast ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is ... has received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval ... Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods ...
(Date:6/23/2016)... 2016   EpiBiome , a precision microbiome engineering ... debt financing from Silicon Valley Bank (SVB). The financing ... advance its drug development efforts, as well as purchase ... "SVB has been an incredible strategic partner to us ... bank would provide," said Dr. Aeron Tynes Hammack ...
(Date:6/23/2016)... ... 23, 2016 , ... In a new case report published today in STEM ... who developed lymphedema after being treated for breast cancer benefitted from an injection of ... dealing with this debilitating, frequent side effect of cancer treatment. , Lymphedema ...
Breaking Biology Technology:
Cached News: